Targeting the production of molecules that promote tumor blood vessel development offers a new path for treating lung cancer.
A metabolic enzyme plays a crucial role in vascular development and may be a good target for cancer therapies.
Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread.
A group of Vanderbilt researchers has used laser technology and a custom-built multiphoton microscope to distinguish breast cancer subtypes and determine if specific therapies are working against the cancer cells in as little as two days.
The nuclear receptor TR3 contributes to ovarian cancer cell death in response to platinum-based chemotherapy – and may be a good target for overcoming cell resistance to certain treatments.
A factor produced by most malignant cells can both promote and inhibit tumor growth – an insight that is critical to using cancer drugs developed to block this factor.